Synairgen Plc (SNG) - Financial and Strategic SWOT Analysis Review

Synairgen Plc (SNG) - Financial and Strategic SWOT Analysis Review


Synairgen Plc (SNG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Synairgen Plc (Synairgen) is a biotechnology company. It is developing innovative therapies for respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and viral infections like COVID-19. The company’s product pipeline includes SNG001, an investigational inhaled interferon beta (IFN-ß) aimed at treating severe viral lung infections by enhancing the body’s antiviral defense. Synairgen’s technological base includes a Biobank with clinical samples from asthma and COPD volunteers, which supports the creation of advanced human disease models and tissue engineering platforms. These models aid in discovering drug targets and supporting clinical trials. Synairgen is headquartered in Southampton, England, United Kingdom.

Synairgen Plc Key Recent Developments

Sep 18,2024: Synairgen : Appointment of New Chairman and Notice of AGM
Sep 18,2024: Synairgen Announces Appointment of New Chairman and Notice of AGM
Sep 05,2024: Synairgen Announces Board Change
Jun 27,2024: Synairgen : Results for the year ended 31 December 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Synairgen Plc - Key Facts
Synairgen Plc - Key Employees
Synairgen Plc - Key Employee Biographies
Synairgen Plc - Major Products and Services
Synairgen Plc - History
Synairgen Plc - Company Statement
Synairgen Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Synairgen Plc - Business Description
Synairgen Plc - Corporate Strategy
Synairgen Plc - SWOT Analysis
SWOT Analysis - Overview
Synairgen Plc - Strengths
Synairgen Plc - Weaknesses
Synairgen Plc - Opportunities
Synairgen Plc - Threats
Synairgen Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Synairgen Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Sep 18, 2024: Synairgen : Appointment of New Chairman and Notice of AGM
Sep 18, 2024: Synairgen Announces Appointment of New Chairman and Notice of AGM
Sep 05, 2024: Synairgen Announces Board Change
Jun 27, 2024: Synairgen : Results for the year ended 31 December 2023
Oct 11, 2023: Synairgen : Appointment of Joseph Colliver as New Chief Financial Officer
Oct 03, 2023: Synairgen plc Appointment of Chief Medical Officer
Sep 21, 2023: Synairgen Announces Interim results for the Six Months Ended 30 June 2023
May 23, 2023: Synairgen plc Posting of Annual Report and Notice of AGM
Apr 17, 2023: Synairgen plc Notice of Full Year results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Synairgen Plc, Key Facts
Synairgen Plc, Key Employees
Synairgen Plc, Key Employee Biographies
Synairgen Plc, Major Products and Services
Synairgen Plc, History
Synairgen Plc, Subsidiaries
Synairgen Plc, Key Competitors
Synairgen Plc, Ratios based on current share price
Synairgen Plc, Annual Ratios
Synairgen Plc, Annual Ratios (Cont...1)
Synairgen Plc, Interim Ratios
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Synairgen Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Synairgen Plc, Ratio Charts
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings